CNCE

CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, February 13, 2023
Class Action Lawsuit, Professional Services, Legal, Sale, CNCE, Fraud, Advertising, Concert, Sun Pharma, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders.
  • On behalf of Concert shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE

Retrieved on: 
Friday, January 20, 2023
Legal, Professional Services, Sale, CNCE, CVR, Concert, KSF

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Concert Pharmaceuticals, Inc. (NasdaqGM: CNCE) to Sun Pharmaceutical Industries Limited.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Concert Pharmaceuticals, Inc. (NasdaqGM: CNCE) to Sun Pharmaceutical Industries Limited.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

ALERT: The M&A Class Action Firm Continues Investigating the Merger – HZNP, ANGN, TIG, CNCE

Retrieved on: 
Wednesday, January 25, 2023
Empire, Amgen, Acquisition, TIG, CNCE, CVR, Monteverde, Therapy, Security (finance), Elicio Berriz

Under the terms of the agreement, HZNP shareholders will receive $116.50 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, HZNP shareholders will receive $116.50 in cash per share they own.
  • It is free and there is no cost or obligation to you.
  • Angion Biomedica Corp. (NASDAQ: ANGN ), relating to its proposed merger with Elicio Therapeutics.
  • Under the terms of the agreement, TIG shareholders are expected to receive $6.15 in cash per share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – ANGN, CNCE, VLON

Retrieved on: 
Saturday, January 21, 2023
Empire, CNCE, Therapy, CVR, Monteverde, Acquisition, Security (finance), Elicio Berriz

Under the terms of the agreement, Elicio shareholders are expected to receive new shares of ANGN, with ANGN shareholders expected to own approximately 34.5% of the combined company.

Key Points: 
  • Under the terms of the agreement, Elicio shareholders are expected to receive new shares of ANGN, with ANGN shareholders expected to own approximately 34.5% of the combined company.
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ), relating to its proposed acquisition by Sun Pharmaceutical Industries Limited.
  • Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ), relating to its proposed merger with GRI Bio, Inc.
  • Under the terms of the agreement, VLON shareholders are expected to own approximately 17% of the combined company.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders

Retrieved on: 
Thursday, January 19, 2023
Class Action Lawsuit, Professional Services, Legal, Sun Pharma, Sale, Concert, Fraud, CNCE, Advertising, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders.
  • On behalf of Concert shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Janus, Disease, Sun Pharma, BSE, NSE, Autoimmune disease, R, CNCE, JAK1, CVR, Depression, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Safety, Deuterium, FDA, Hair loss, NDA, Woman, Immune system, Scalp, Food, Patient, CVR Partners, JAK2, Sale, Acquisition, Multimedia, Janus kinase, Reuters, Alopecia areata, Life, Investment, Concert, Hair, Wardwell, Security (finance), Pharmaceutical industry, Ophthalmology

Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.

Key Points: 
  • Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime1,2,3.
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib,” said Abhay Gandhi, CEO North America, Sun Pharma.
  • “There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert’s commitment to supporting the Alopecia Areata patient community.

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

Retrieved on: 
Monday, November 21, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, CNCE, Medication, Yale School of Medicine, Week, Scalp, Disease, Alopecia areata, Hair loss, Congress, Degenerative disease, Hair, SALT, World Congress, Patient, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12th World Congress for Hair Research.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12th World Congress for Hair Research.
  • The presentation highlights THRIVE-AA1 study results evaluating Concerts investigational oral medicine deuruxolitinib (CTP-543) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.
  • The World Congress presentation includes new analyses from THRIVEAA1 showing the effect of deuruxolitinib on regrowth of scalp hair based on disease severity and duration of current episode of hair loss.
  • Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease.

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 9, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Investor, Conference, NASDAQ, Alopecia areata, Company, CNCE, Medication, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.
  • A webcast of the presentation may be accessed in the Investors section of the Companys website at www.concertpharma.com .
  • Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor.
  • Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease.